Human fetal skin-derived stem cell secretome reduce liver fibrosis by regulating TGF- β /Smad signal pathway

Xia Yao

Affiliated Hospital of Changchun University of Chinese Medicine

Jing Wang

Affiliated Hospital of Changchun University of Chinese Medicine

Jiajing Zhu

China-Japan Union Hospital of Jilin University

Xiaoli Rong (✉ rongxl16@mails.jlu.edu.cn)

Johns Hopkins University

Research

Keywords: hFSSC, secretome, liver fibrosis, TGF- β /Smad

Posted Date: March 27th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-19079/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Liver fibrosis resulting from chronic liver injury is one of the major causes of mortality worldwide. Stem cells-secreted secretome has been evaluated for overcoming the limitations of cell-based therapy in hepatic disease, while maintaining its advantages.

Methods: In this study, we investigated the effect of human fetal skin-derived stem cells (hFFSCs) secretome in the treatment of liver fibrosis. To determine the therapeutic potential of the hFFSCs secretome in liver fibrosis, we established the CCl₄-induced rat liver fibrosis model, and administered hFFSCs secretome in vivo. Moreover, we investigated the anti-fibrotic mechanism of hFFSCs secretome in hepatic stellate cells (HSCs).

Results: Our results showed that hFFSCs secretom effectively reduced collagen content in liver, improved the liver function and promoted liver regeneration. In addition, we found that hFSSC secretom inhibited the TGF- β 1, Smad2, Smad3, and Collagen I expression, however, increased Smad7 expression.

Conclusions: In conclusions, our results suggest that hFFSCs secretome treatment could reduce CCl₄-induced liver fibrosis via regulating the TGF- β /Smad signal pathway.

Introduction

Liver fibrosis is a wound healing response generated against chronic or iterative liver injury[1]. Recent evidence suggests that stem cell-based liver fibrosis treatment can be mediated through paracrine effects[2, 3]. The exclusive use of stem cell-secreted secretome, has been evaluated for overcoming the limitations of cell-based therapy, while maintaining its advantages to their parent cells[4]. It included that extracellular vesicles, and other soluble proteins or biologically active molecules. In addition, previous studies have indicated that human bone marrow mesenchymal stem cells-derived exosomes and other stem cells-derived secretome can recued liver fibrosis[5, 6].

Previous studies have indicated that the features of fetal tissue cells facilitate engraftment in vivo and may provide preferred effects against diseases difficult to treat[7]. Since 1928, hundreds of clinical trials using various types of fetal transplants have been performed worldwide[8–10]. Moreover, recently studies have been demonstrated that human fetal stem cells have a great growth promoting potential, which benefited to the tissue regeneration and cell therapy[11, 12]. In comparison to other mesenchymal stem cell (MSCs), fetal stem cells (FSCs) are easier to culture and more readily proliferate, and less likely to be rejected by transplant recipients, as these cells are less antigenic[8]. Although there remain still ethical and social issues with respect to the clinical use of fetal tissue, fetal stem cell secretome transplantation may overcome these problems and have more perspectives on hepatic disease treatment.

In our previous study, we have successfully isolated and identified hFSSCs[13]. Interestingly, we found hFSSC secretome has great ability to control and balance the collagen formation in skin tissue[13]. Therefore, we hypothesis that hFSSC have a potential to reduce the collagen formation in liver fibrosis,

whereas liver fibrosis is caused by over-abundance of collagen. We further analyzed the effects of hFSSC secretome on liver fibrosis in vitro, and investigated the mechanism of hFSSC secretome and TGF- β /Smad pathway involvement on anti-fibrosis. Our preliminary results provide the first evidence that hFSSCs secretome effectively reduce liver fibrosis through the TGF- β /Smad pathway. We believe that the hFSSCs secretome as an acellular regenerative therapy and approaches can provide great potential for the treatment of liver fibrosis.

Materials And Methods

Cell culture

hFSSCs and human umbilical cord mesenchymal stem cell (hUCMSCs) were provided and extracted by our previous study[13]. HSCs were purchased from the Chinese Academy of Medical Sciences, China. In brief, hFSSCs, hUCMSCs and HSCs were cultured in DMEM (Gibco, Grand island, U.S.) supplemented with 500 U/ml penicillin and 500 μ g/ml streptomycin (Invitrogen, Shanghai, China), and 10% FBS (Gibco, Grand island, U.S.) at 37°C, with saturated humidity and 5% CO₂. hFSSCs and hUCMSCs at the P5 were used for this study, and hFSSCs and hUCMSCs secretome was collected as reported in our previous study[13].

CCl₄-induced liver fibrosis in rats

Liver fibrosis was induced in Sprague Dawley (SD) rats (8-week old, female, 200g). All protocols and procedures were approved by the Animal Experiment Ethic Committee of Changchun University of Traditional Chinese Medicine (Approval NO. XW201903167). Detailed procedures for CCl₄-induced have been described in our published studies[6]. Briefly, rats were administered with an intraperitoneal injection of 30% CCl₄, 3ml/kg body weight twice weekly in olive oil. After eight weeks, CCl₄ treated rats were randomly assigned into three groups (n=10 rats, tail vein injection/weekly): PBS group (1ml); hUCMSC secretome group (250 μ g, 1ml); hFSSC secretome group (250 μ g, 1ml). After 4 weeks, liver tissue and serum were collected. Livers were divided into two parts of preservation in 10% formalin and freezing at -80 °C.

Histopathological analysis

Liver tissues were processed for paraffin embedding by slicing into 4 μ m sections. Liver sections were stained with hematoxylin & eosin (H&E) and Masson according to standard protocols. We selected the liver section fields randomly to analyze the liver fibrosis. The percentage of collagen stained area was calculated via Image-Pro Plus. Immunohistochemistry (IHC) was measured with the Kit (Maixin KIT-9710, Fuzhou, China) in accordance with the manufacturer's instructions. In brief, the liver sections were deparaffinized, rehydrated, and incubated in a 99 °C water bath for 15 minutes. Then, the slide was incubated with 3% H₂O₂ for 15 minutes, and blocked with 10% normal goat serum for 1 h at 37 °C. Following with the incubation of primary antibody against PCNA (ab15497, 1:500 dilution, Abcam,

Cambridge, UK) and α -SMA (ab5694, 1:500 dilution, Abcam, Cambridge, UK) overnight at 4 °C. Next, slides were incubated with biotinylated goat-anti-rabbit IgG antibody. Add diaminobenzidine solution for 15 minutes at 37 °C, then incubated with avidin peroxidase reagent, and hematoxylin for counterstaining. Lastly, slides were photographed using an optical microscope (Olympus, Tokyo Metropolitan, Japan). We used 10 random fields per section and 10 sections in total (n=10 rats) for quantification of IHC results. The IHC results were calculated via Image-Pro Plus.

Biochemical analysis

The serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total protein (TP), total bilirubin (TBIL), alkaline phosphatase (ALP), gamma glutamyl transpeptidase (γ -GT) were assessed using the Automated Biochemical Analyzer (AU-680, Beckman, California, U.S.) according to the procedure. Liver homogenate (10%, w/v) was prepared by homogenizing the right lobe of liver on ice in 150 mM Tris-HCl buffered saline (pH 7.2) using a polytron homogenizer (PT3100D; Kinematical, Lucerne, Switzerland). The levels of Malondialdehyde (MDA) and Hydroxyproline (Hyp) in liver tissue were measured using kits (NanJing JianCheng Bio., Nanjing, China) according to the manufacturer's instructions.

Quantitative real-time PCR (qRT-PCR)

Total RNA was isolated from liver tissue using Trizol reagent (Invitrogen, Shanghai, China) according to the manufacturer's protocol. Then, 1 μ g total RNA was reverse-transcribed to give cDNA, which was used as the template, and combined with standard SYBR premix Ex Taq (Invitrogen, Shanghai, China) on the Real-Time PCR Detection System (Roche, Basel, Switzerland), and experiments were conducted in triplicate. The primers are listed in Table S1, and GAPDH served as the internal control. All reactions were performed in triplicate and the data were analyzed using the $2^{-\Delta\Delta C_t}$ method.

Immunofluorescence (IF) staining

When HSCs reached 60~70% confluence on 24-well plates, they were cultured with hBM-MSCs-Ex (5ng/ml) for 48h. Next, HSCs were incubated with 4% paraformaldehyde at room temperature for 10 minutes, and then incubated with 1% bovine serum albumin (BSA, Biosharp, Wuhan, China) for 30 minutes. Cells were incubated with a primary antibody against α -SMA (ab5694, 1:100 dilution, Abcam, Cambridge, UK) for 1h, followed by incubation with a secondary antibody (goat anti-rabbit IgG, ab15007, 1:500 dilution, Abcam, Cambridge, UK) for 30 minutes at room temperature. Rhodamine phalloidin (Thermal Scientific, Waltham, U.S.) was stained for cytoskeleton. The nuclei were labeled with DAPI (Thermal Scientific, Waltham, U.S.). Fluorescent images were captured using an EVOS Cell Imaging System (Thermo Scientific, Waltham, U.S.).

Western blotting

HSCs were co-cultured with either SFM, hBM-MSCs, hBM-MSCs-Ex (5ng/ml) for 48h before samples were collected for protein extraction. Liver tissue was collected from each treatment group (liver fibrosis, hBM-MSCs, and hBM-MSCs-Ex group) for protein extraction. Protein samples were mixed with SDS sample buffer and heated to 95 °C for 10 minutes, followed by separation on SDS-polyacrylamide gels. Resolved proteins were electro-blotted onto nitrocellulose membrane and probed with antibodies against PPAR γ (ab 23673), Wnt3a (ab 248472), Wnt10b (ab70816), β -catenin (ab32572), WISP1 (ab50041), Cyclin D1 (ab16663), α -SMA (ab5694), Collagen I (ab138492) and GAPDH (ab 8245) overnight at 4°C (1:1000 dilution, Abcam, Cambridge,UK). Nitrocellulose membranes were then incubated with a secondary antibody, HRP-conjugated goat anti-rabbit IgG (ab15007), at room temperature for 2h, and visualized by chemiluminescent detection according to the manufacturer's instructions (Immobilon western chemiluminescent HRP substrate, Millipore, Massachusetts, U.S.).

Statistical analysis

Statistical analysis was performed using GraphPad Prism Version 6. One-way ANOVA with Dunnett's multiple comparisons test was used to test for statistically significant differences. All quantitative data are expressed as mean $\pm$ SD. $p < 0.05$ was considered to be statistically significant.

Results

hFSSC secretome reduced CCl₄-induced liver fibrosis in rats.

To explore the effect of hFSSC secretome on liver fibrosis, we using CCl₄-induced a liver fibrosis model in rats (Fig. 1a). Compared to the PBS group, gross morphology changes obviously in hFSSC secretome group, including less fibrous nodular and more ruddy on the surface, more uniform surface and soft texture (Fig. 1b). After 4 weeks treatment, histopathologic analysis using Masson staining indicated that the collagen area percentage in hFSSC group (9.2%) was significantly reduced, compared to the other two control groups (24.3% in PBS group and 14.9% in hUCMSC secretome group, Fig. 1b and 1c, $p < 0.05$).

To further verify the roles of hFSSC secretom in the pathogenesis of liver fibrosis, we performed immunofluorescence staining of TGF- β in HSCs. As TGF- β 1 is considered as a crucial mediator in tissue fibrosis, and HSCs are one of the major effector cells in liver fibrosis. We found that hFSSC secretome group reduced fluorescence intensity observably, compared to the other two control groups. Furthermore, we detected the MDA (a marker for oxidative stress and liver cell injury) and Hyp (a main component in collagen tissue) content in the liver tissue. We found that the level of MDA and Hyp in hFSSC secretome group was significantly lower than the other two control groups (Fig. 2b and 2c $p < 0.01$). These findings suggest that hFSSC secretome effectively reduced CCl₄-induced liver fibrosis in rats.

hFSSC secretome improved liver functionality and promoted liver regeneration

To explore the effect of hFSSC secretome on liver functionality, we performed the biochemical analyses. In comparison to the PBS group, hFSSC secretome group significantly reduced serum levels of ALT, AST,

TBIL, γ -GT and ALP (Fig. 3a-3e, $p < 0.05$). However, the serum level of TP in hFSSC secretome group was higher than that in PBS group (Fig. 3f, $p < 0.05$). In addition, hFSSC secretome group significantly reduced the serum levels of TBIL and γ -GT compared to hUCMSC secretome group (Fig. 3c and 3d, $p < 0.05$). These results suggest that hFSSC secretome effectively improved liver functionality.

Next, we performed IHC to assess the effects of the hFSSC secretome on the liver. α -SMA is an important indicator of the occurrence and development of hepatic fibrosis. IHC results showed that the percentage of α -SMA positive area in hFSSC secretome group (0.82%) was significantly decreased compared to the PBS group (5.51%, Fig. 4a and 4b, $p < 0.001$). PCNA is an crucial indicator of hepatocyte proliferation. IHC results showed that the percentage of PCNA positive area in hFSSC secretome group (4.13 %) was significantly increased compared to the PBS group (7.48%, Fig. 4a and 4c, $p < 0.01$). The histological results indicated that hFSSC secretome effectively delayed the progression of liver fibrosis, and promoted the liver regeneration.

hFSSC secretome regulate the TGF- β /Smad signal pathway

To investigate the underlying mechanism of the effect of hFSSC secretome on liver fibrosis, we performed the Western blot and RT-qPCR to analysis the expression of TGF- β 1, Smad2, Smad3, Smad7 and Collagen I in HSCs, as it is one of the major effector cells in liver fibrosis. We found that TGF- β 1, Smad2, Smad3, and Collagen I expression was significantly decreased in hFSSC secretome group, compared that of PBS group (Fig. 5a and 5b, $p < 0.001$). However, we detected the Smad7 was significantly increased in hFSSC secretome group, compared that of the other two control groups (Fig. 5a and 5b, $p < 0.01$). Smad7 serves as a negative feedback regulator of TGF- β 1/Smad pathway, thereby protects against TGF- β 1-mediated fibrosis (Fig. 6). These results suggest that hFSSC secretome effectively reduced liver fibrosis via regulating the TGF- β /Smad signal pathway (Fig5).

Discussion

In this study, our results demonstrated that hFSSC secretom reduce liver fibrosis both in rats. Moreover, our research illustrated that hFSSC secretom reduce liver fibrosis through regulating the TGF- β /Smad signal pathway in HSCs.

Recent evidence indicates that the mesenchymal stem cell secretome as an acellular regenerative therapy for liver disease[5, 14]. The use of MSC secretome has been shown to have anti-fibrotic effects[14]. Moreover, IV injection of hucMSC-EVs decreased liver fibrosis, reduced apoptosis and mitigated liver damage induced by CCl₄ in mice[15, 16]. In our study, we found that hFSSC secretom effectively reduced CCl₄-induced liver fibrosis, and improved liver functionality in rats (Fig. 1). Moreover, hFFSCs secretomes treatment is more effective than of hUCMSCs secretomes in resolving fibrosis, such as some indicators included collagen area, MDA, Hyp, TBIL, and γ -GT. The reasons that differences found between hUCMSCs and hFFSCs secretomes may be reported that hFFSCs secretomes contains more biological activity

factors than hUCMSCs secretomes[13]. Our studies indicated that hFSSC secretome is an attractive emerging option for therapeutic applications as a therapeutic strategy for liver fibrosis.

Previous study that mesenchymal stem cell secretome inhibit HSC activation and promoted liver regeneration[17–19]. HSCs stimulate the production of a large amount of collagen fibers to form liver fibrosis. Moreover, positive expression of α -SMA can serve as a marker for HSCs activation[20]. Our results demonstrate that hFSSC secretome decreased α -SMA expression. PCNA is an crucial indicator of hepatocyte proliferation[15]. Our study demonstrate that the percentage of PCNA positive area was significantly increased after hFSSC secretome treatment. These results confirmed that hFSSC secretome promotes liver regeneration while reducing fibrosis. Despite our results confirming that hFSSC secretome had significantly reduced liver fibrosis and caused no detectable immunological responses, their exact mechanisms of action need further exploration.

TGF- β 1/Smad pathway is an important pathogenic mechanism in tissue fibrosis[21, 22]. Studies have shown that TGF- β 1 is considered as a crucial mediator in tissue fibrosis and causes tissue scarring largely by activating its downstream small mother against decapentaplegic (Smad) signaling[23]. However, different TGF- β signalings play different roles in fibrogenesis[22]. TGF- β 1 directly activates Smad signaling which triggers pro-fibrotic gene overexpression[24]. Increasing studies have demonstrated that dysregulation of TGF- β 1/Smad pathway was an important pathogenic mechanism in tissue fibrosis[25]. Smad2 and Smad3 are the two major downstream regulator that promote TGF- β 1-mediated tissue fibrosis, while Smad7 serves as a negative feedback regulator of TGF- β 1/Smad pathway thereby protects against TGF- β 1-mediated fibrosis[22]. Our findings proved that hFSSC secretome effectively reduced TGF- β 1, Smad2, Smad3, and Collagen I expression, moreover, increased Smad7 expression. It indicated that hFSSC secretome effectively reduced liver fibrosis via regulating the TGF- β /Smad signal pathway (Fig. 6).

In conclusion, we successfully investigated the role of hFSSC secretome on cutaneous liver fibrosis. Our results demonstrated that hFSSC secretome can exert promoting effect of liver fibrosis via regulating the TGF- β /Smad signal pathway.

Abbreviations

hFSSC: Human fetal skin-derived stem cell; MSCs: mesenchymal stem cells; hUCMSCs: human umbilical cord mesenchymal stem cell; HSCs: Hepatic stellate cells; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; γ -GT: Gamma glutamyl transpeptidase; ALP: Alkaline phosphatase; TP: Total protein; Hyp: Hydroxyproline; MDA: Malonaldehyde; qRT-PCR: Quantitative real-time PCR; α -SMA: Alpha-smooth muscle actin

Declarations

Ethics approval and consent to participate

All the protocols and procedures were approved by the Animal Experiment Ethics Committee of the Changchun University of Traditional Chinese Medicine, China (Approval NO. XW201903167). The informed written consent form was approved by the Clinical Research Ethics Committee and signed by the donor before sample collection.

Consent for publication

Not applicable.

Availability of supporting data

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Competing interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

This work was supported by the National Natural Science Foundation of China (No.8762069).

Authors' Contributions

X.Y. carried out the cell culture and animal studies, and helped to draft the manuscript. J.W. carried out animal studies and qRT-PCR. J.Z. carried out WB and performed the statistical analysis. X.R. conceived of the study, and participated in its design and coordination and helped to draft the manuscript

Acknowledgments

The authors thank Professor Chen, Changchun University of Traditional Chinese Medicine, for his assistance in animal experiment.

References

1. Sun M, Kisseleva T: **Reversibility of liver fibrosis**. Clinics and research in hepatology and gastroenterology 2015, **39 Suppl 1**:S60-63.
2. Arriazu E, Ruiz de Galarreta M, Cubero FJ, Varela-Rey M, Perez de Obanos MP, Leung TM, Lopategi A, Benedicto A, Abraham-Enachescu I, Nieto N: **Extracellular matrix and liver disease**. Antioxid Redox Signal 2014, **21**(7):1078-1097.
3. Elpek GO: **Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update**. World J Gastroenterol 2014, **20**(23):7260-7276.

4. Konala VB, Mamidi MK, Bhonde R, Das AK, Pochampally R, Pal R: **The current landscape of the mesenchymal stromal cell secretome: A new paradigm for cell-free regeneration.** *Cytotherapy* 2016, **18**(1):13-24.
5. Driscoll J, Patel T: **The mesenchymal stem cell secretome as an acellular regenerative therapy for liver disease.** *Journal of gastroenterology* 2019, **54**(9):763-773.
6. Rong X, Liu J, Yao X, Jiang T, Wang Y, Xie F: **Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/beta-catenin pathway.** *Stem Cell Res Ther* 2019, **10**(1):98.
7. Moerkamp AT, Lodder K, van Herwaarden T, Dronkers E, Dingenouts CK, Tengstrom FC, van Brakel TJ, Goumans MJ, Smits AM: **Human fetal and adult epicardial-derived cells: a novel model to study their activation.** *Stem Cell Res Ther* 2016, **7**(1):174.
8. Ishii T, Eto K: **Fetal stem cell transplantation: Past, present, and future.** *World J Stem Cells* 2014, **6**(4):404-420.
9. Zhang ZY, Teoh SH, Hui JH, Fisk NM, Choolani M, Chan JK: **The potential of human fetal mesenchymal stem cells for off-the-shelf bone tissue engineering application.** *Biomaterials* 2012, **33**(9):2656-2672.
10. Xu J, Wang B, Sun Y, Wu T, Liu Y, Zhang J, Lee WY, Pan X, Chai Y, Li G: **Human fetal mesenchymal stem cell secretome enhances bone consolidation in distraction osteogenesis.** *Stem Cell Res Ther* 2016, **7**(1):134.
11. Chan J, O'Donoghue K, de la Fuente J, Roberts IA, Kumar S, Morgan JE, Fisk NM: **Human fetal mesenchymal stem cells as vehicles for gene delivery.** *Stem cells (Dayton, Ohio)* 2005, **23**(1):93-102.
12. Wang X, Jiao Y, Pan Y, Zhang L, Gong H, Qi Y, Wang M, Gong H, Shao M, Wang X et al: **Fetal Dermal Mesenchymal Stem Cell-Derived Exosomes Accelerate Cutaneous Wound Healing by Activating Notch Signaling.** *Stem Cells Int* 2019, **2019**:2402916.
13. Rong X, Li J, Yang Y, Shi L, Jiang T: **Human fetal skin-derived stem cell secretome enhances radiation-induced skin injury therapeutic effects by promoting angiogenesis.** *Stem Cell Res Ther* 2019, **10**(1):383.
14. Jang YJ, An SY, Kim JH: **Identification of MFGE8 in mesenchymal stem cell secretome as an anti-fibrotic factor in liver fibrosis.** *BMB reports* 2017, **50**(2):58-59.
15. Li T, Yan Y, Wang B, Qian H, Zhang X, Shen L, Wang M, Zhou Y, Zhu W, Li W et al: **Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis.** *Stem cells and development* 2013, **22**(6):845-854.
16. Lou G, Chen Z, Zheng M, Liu Y: **Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases.** *Exp Mol Med* 2017, **49**(6):e346.
17. Li Q, Zhou X, Shi Y, Li J, Zheng L, Cui L, Zhang J, Wang L, Han Z, Han Y et al: **In vivo tracking and comparison of the therapeutic effects of MSCs and HSCs for liver injury.** *PLoS One* 2013, **8**(4):e62363.

18. Berardis S, Dwisthi Sattwika P, Najimi M, Sokal EM: **Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects.** World J Gastroenterol 2015, **21**(3):742-758.
19. Eom YW, Shim KY, Baik SK: **Mesenchymal stem cell therapy for liver fibrosis.** Korean J Intern Med 2015, **30**(5):580-589.
20. Bataller R, Brenner DA: **Liver fibrosis.** Journal of Clinical Investigation 2005, **115**(2):209-218.
21. Hu HH, Chen DQ, Wang YN, Feng YL, Cao G, Vaziri ND, Zhao YY: **New insights into TGF-beta/Smad signaling in tissue fibrosis.** Chemico-biological interactions 2018, **292**:76-83.
22. Walton KL, Johnson KE, Harrison CA: **Targeting TGF-beta Mediated SMAD Signaling for the Prevention of Fibrosis.** Frontiers in pharmacology 2017, **8**:461.
23. Mokoena D, Dhillip Kumar SS, Houreld NN, Abrahamse H: **Role of photobiomodulation on the activation of the Smad pathway via TGF-beta in wound healing.** Journal of photochemistry and photobiology B, Biology 2018, **189**:138-144.
24. Grotendorst GR: **Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts.** Cytokine & growth factor reviews 1997, **8**(3):171-179.
25. Lindert S, Wickert L, Sawitza I, Wiercinska E, Gressner AM, Dooley S, Breitkopf K: **Transdifferentiation-dependent expression of alpha-SMA in hepatic stellate cells does not involve TGF-beta pathways leading to coinduction of collagen type I and thrombospondin-2.** Matrix Biol 2005, **24**(3):198-207.

Figures

Figure 1

hFSSC secretome reduced liver fibrosis in rats. a. Experimental design. b. The representative images of gross morphology and Masson staining analysis of liver. Bar = 1 mm), n = 10 rats. c. Quantitative analysis of the collagen area percentage at 4 weeks. *p<0.05, **p<0.01, ***p<0.001. n = 10; mean ± SD.

b

c

Figure 2

hFSSC secretome reduced liver fibrosis index. a. Representative images of immunofluorescence staining performed for TGF- β in HSCs. Bar =200 μ m. b,c Quantitative analysis of hepatic MDA and Hyp content. **p<0.01, ***p<0.001. n = 10, mean $\pm$ SD.

Figure 3

hFSSC secretome improves liver function in serum biochemical parameters. a. ALT: Alanine aminotransferase. b. AST: Aspartate aminotransferase. c. TBIL: Total bilirubin. d. γ -GT: Gamma glutamyl transpeptidase. e. ALP: Alkaline phosphatase. f. TP: Total protein. *p<0.05, **p<0.01, ***p<0.001. n = 10, mean $\pm$ SD.

Figure 4

Histological analysis of hFSSC secretome reduced liver fibrosis and promoted liver regeneration. a Photomicrographs of liver tissue sections showing IHC staining for α -SMA and PCNA. Brown cells represent the positive expression, bar = 1mm. . b, c. The quantification of α -SMA and PCNA positive cells area**p<0.01, ***p<0.001. n = 10, mean $\pm$ SD.

Figure 5

hFSSC secretome inhibited the TGF- β /Smad signaling pathway in HSCs. a. Representative western blotting analysis the expression of TGF- β 1, Smad2, Smad3, Smad7 and Collagen I in HSCs. b. Relative mRNA expression levels of TGF- β 1, Smad2, Smad3, Smad7 and Collagen I in HSCs. ** $p < 0.001$, *** $p < 0.0001$. n = 3, mean $\pm$

Figure 6

hFSSC secretome reduced liver fibrosis by regulating the TGF-β/Smad signaling pathway. hFSSC secretom inhibited TGF-β1 expression, and activated Smad7 expression which are activated by the binding of the TGF-β super family to the cell surface receptors. TGF-β1-mediated tissue fibrosis via Smad2/Smad3 which the two major downstream regulator, while Smad7 serves as a negative feedback regulator of TGF-β1/Smad pathway, thereby protects against TGF-β1-mediated fibrosis. Furthermore, hFSSC secretom decreased the collagen I expression, thereby reduce liver fibrosis.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryMaterial.docx](#)